Inovio Pharmaceuticals (INO) EPS (Basic) (2010 - 2026)
Inovio Pharmaceuticals' (INO) quarterly EPS (Basic) came in at -$0.22 in Q2 2026, up 61.34% year-over-year from -$0.14 in Q2 2025, and up 29.56% quarter-over-quarter from -$0.32 in Q1 2026.
Powered by 
Analysis
Inovio Pharmaceuticals (INO) EPS (Basic) (2010 - 2026) Analysis & Trends
Inovio Pharmaceuticals has disclosed EPS (Basic) across 17 years of filings, most recently posting -$0.22 for Q2 2026.
- In Q2 2026, EPS (Basic) rose 61.34% year-over-year to -$0.22; the TTM figure through Jun 2026 stood at -$0.95 (up 60.27% YoY), while the FY2025 annual figure was -$1.8, up 54.65% from the prior year.
- EPS (Basic) came in at -$0.22 for Q2 2026 at Inovio Pharmaceuticals, up from -$0.32 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$0.22 in Q2 2026 to a low of -$5.53 in Q2 2022.
- Average EPS (Basic) over 5 years is -$1.51, with a median of -$1.17 recorded in 2024.
- Year-over-year, EPS (Basic) plunged 31.75% in 2022 and soared 70.85% in 2023.
- Over 5 years, EPS (Basic) stood at -$2.74 in 2022, then jumped by 58.83% to -$1.13 in 2023, then surged by 36.28% to -$0.72 in 2024, then jumped by 49.46% to -$0.36 in 2025, then surged by 38.39% to -$0.22 in 2026.
- Per Business Quant data, the three most recent EPS (Basic) figures were -$0.22 in Q2 2026, -$0.32 in Q1 2026, and -$0.36 in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 206.44 Bn | 192.45 Bn | 7.24 Bn | 4.40 |
| 2 | Gilead Sciences | 179.97 Bn | 176.79 Bn | 6.22 Bn | -8.44 |
| 3 | Vertex Pharmaceuticals | 130.57 Bn | 122.72 Bn | 2.84 Bn | 4.34 |
| 4 | Regeneron Pharmaceuticals | 81.63 Bn | 73.63 Bn | 3.93 Bn | 12.62 |
| 5 | Argenx Se | 60.34 Bn | 55.16 Bn | 1.37 Bn | 7.70 |
| 6 | Moderna | 54.37 Bn | 49.23 Bn | 52.00 Mn | -1.96 |
| 7 | Alnylam Pharmaceuticals | 33.07 Bn | 29.76 Bn | 992.69 Mn | 1.23 |
| 8 | Biogen | 31.84 Bn | 30.55 Bn | 1.96 Bn | 0.66 |
| 9 | Roivant Sciences | 29.49 Bn | 29.49 Bn | 1.16 Mn | -0.40 |
| 10 | Inovio Pharmaceuticals | 104.88 Mn | 104.88 Mn | - | -0.22 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -0.22 |
| Mar 31, 2026 | -0.32 |
| Dec 31, 2025 | -0.36 |
| Sep 30, 2025 | -0.40 |
| Jun 30, 2025 | -0.58 |
| Mar 31, 2025 | -0.65 |
| Dec 31, 2024 | -0.72 |
| Sep 30, 2024 | -0.93 |
| Jun 30, 2024 | -1.22 |
| Mar 31, 2024 | -1.36 |
| Dec 31, 2023 | -1.13 |
| Sep 30, 2023 | -1.52 |
| Jun 30, 2023 | -1.61 |
| Mar 31, 2023 | -1.89 |
| Dec 31, 2022 | -2.74 |
| Sep 30, 2022 | -1.82 |
| Jun 30, 2022 | -5.53 |
| Mar 31, 2022 | -4.22 |
| Dec 31, 2021 | -6.15 |
| Sep 30, 2021 | -3.43 |